Skip to content
Biodatica
Start free

Solstice Oncology, Inc.

BOSTON, MA

OncologyFormed
Compare Sign in to watch

What changed

$121M raise filed (Form D)

4mo agoRaise filed (Form D)Mar 9, 2026Source filing (opens the source filing in a new tab)

Momentum

55no change

Momentum 55 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

~120months

The last disclosed raise still models out past a year.

Stage

Formed

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

17 pre-ticker oncology companies at Formed

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Filing

    Form D · $121M

    Mar 9, 2026

    Solstice Oncology, Inc. · private raise, self-reported by the issuer

    SEC EDGAR · 0002116600-26-000002 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources